Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer by Moench, Romana et al.
Oncotarget68749www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 42
Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient 
to prevent PDGF-mediated effects on glycolysis and proliferation 
in colorectal cancer
Romana Moench1, Tanja Grimmig1, Vinicius Kannen2, Sudipta Tripathi3, Marc Faber1, 
Eva-Maria Moll1,†, Anil Chandraker3, Reinhard Lissner1, Christoph-Thomas Germer4, 
Ana Maria Waaga-Gasser1,3,*, Martin Gasser4,*
1Department of Surgery I, Molecular Oncology and Immunology, University of Wuerzburg, Wuerzburg, Germany
2Ribeirao Preto Pharmaceutical Sciences School, Department of Toxicology, Bromatology, and Clinical Analysis, University of 
Sao Paulo, Sao Paulo, Brazil
3Brigham and Women’s Hospital, Transplant Research Center, Harvard Medical School, Boston, MA, USA
4Department of Surgery I, University of Wuerzburg, Wuerzburg, Germany
†Post mortem
*These authors have contributed equally to this work and shared senior authorship
Correspondence to: Ana Maria Waaga-Gasser, email: waaga_a@ukw.de
Keywords: PDGF, colorectal cancer, PI3K/Akt/mTOR, MAPK pathway, glucose metabolism
Received: January 21, 2016     Accepted: August 08, 2016     Published: September 08, 2016
ABSTRACT
Platelet-derived growth factor (PDGF) and signaling via its receptors plays a 
crucial role in tumor cell proliferation and thus may represent an attractive target 
besides VEGF/EGFR-based antibody therapies. In this study we analyzed the influence 
of PDGF in colorectal cancer. PDGF was expressed intensively in early and even more 
intensively in late stage primary CRCs. Like VEGF, PDGF enhanced human colon cancer 
proliferation, and increased oxidative glycolytic activity, and activated HIF1a and 
c-Myc in vitro. PDGF activated the PI3K/Akt/mTOR pathway while leaving MAPK 
signaling untouched. Further dissection showed that inhibition of Akt strongly 
impeded cancer cell growth while inhibition of PI3K did not. MAPK analysis suggested 
an inhibitory crosstalk between both pathways, thus explaining the different effects 
of the Akt and PI3K inhibitors on cancer cell proliferation. PDGF stimulates colon 
cancer cell proliferation, and prevents inhibitor induced apoptosis, resulting in tumor 
growth. Therefore inhibition of PDGF signaling seems to be a promising target in 
colorectal cancer therapy. However, due to the multifaceted nature of the intracellular 
PDGF signaling, careful intervention strategies are needed when looking into specific 
signaling pathways like PI3K/Akt/mTOR and MAPK.
INTRODUCTION
Intensive research has been focused on new treatment 
strategies in colorectal cancer. Primarily VEGF (Vascular 
Endothelial Growth Factor), EGF (Epidermal Growth Factor) 
and their receptors [1–4] have been screened as potential 
therapeutic targets. As a result, inhibitory monoclonal 
antibodies as well as tyrosine kinase inhibitors have 
shown promising outcome in therapy of colorectal cancer 
(CRC) patients [5]. For example, the monoclonal antibody 
Bevacizumab intercepts VEGF before binding to his VEGF 
receptor and thus inhibits activation of intracellular signaling, 
e.g. the PI3K/Akt/mTOR pathway, and angiogenesis [1, 2]. 
Besides VEGF, recent studies indicated that also the Platelet 
Derived Growth Factor (PDGF) influences the tumor cell 
proliferation and metabolism [6].
Possible downstream signaling pathways targeted by 
PDGF are the PI3K/Akt/mTOR pathway [7] and the MAPK 
pathway [8] - maintaining diverse crosstalk points with each 
other [9, 10]. A PDGF-induced activation of the PI3K/Akt/
mTOR pathway influences not only growth, proliferation, 
and survival, but also shifts in energy metabolism, 
biosynthesis of macromolecules, and cell cycle progression 
[11–13].
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The downstream target of PI3K/Akt/mTOR signaling, 
hypoxia-inducible-factor 1α (HIF1α), can influence 
glucose metabolism not only under hypoxic but also under 
normoxic conditions [14]. HIF1α triggers both, VEGF 
secretion, [15] and the expression of glycolytic markers 
which exert influence on the glycolytic rate in tumor cells. 
This leads to the synthesis of macromolecules and increased 
tumor cell proliferation (Warburg effect) [16, 17].
As demonstrated in various studies, PDGF and 
its receptors were expressed on tumor cells and in 
surrounding tissue (stroma and pericytes) in colon 
cancer [18–21]. This suggests not only paracrine but also 
autocrine PDGF stimulation of cancer cells, which can 
boost proliferation, supporting the direct effects of PDGF 
on tumor cells [22].
To understand the impact of PDGF in CRC, the 
purpose of this study was to elucidate the influence of 
PDGF on intracellular signaling, proliferation, and cell 
metabolism in colorectal cancer, and in particular on the 
PI3K/Akt/mTOR.
RESULTS
PDGF and VEGF expression in primary human 
colon cancer and in colon cancer cell lines
To analyze the fundamental role of PDGF in CRC, 
we first investigated PDGF and VEGF gene expression. 
Both PDGF and VEGF were significantly overexpressed 
in CRC samples compared to normal mucosa (p<0.001) 
(Figure 1A and 1B), with PDGF showing a tendency of 
increased expression in advanced tumors compared to 
earlier stage cancers (UICC III/IV vs. UICC I/II). The 
immunofluorescence double staining in colon cancer cells 
(UICCIII/IV) with PDGF in combination with Cytokeratin 
illustrated a clear PDGF expression in epithelial colon 
cancer cells while PDGF expression in the stromal region 
(Vimentin staining) was considerably lower or absent. 
VEGF exhibited the same positive expression in the colon 
cancer tissue, whereas the expression intensity of PDGF 
was comparable with the VEGF expression intensity 
(Figure 1C). DAB- and immunofluorescent analysis 
of HT29 colon cancer cells also demonstrated tumor 
cell related expression of VEGF and PDGF (Figure 1D 
and 1E).
Influence of PDGF stimulation and Akt-pathway 
inhibition on proliferation in HT29 cells
MTS proliferation analysis (Figure 2J) of HT29 
cells confirmed an increased proliferative response after 
both PDGF- and VEGF-stimulation (p<0.05 after 24h). 
Combined stimulation with PDGF and VEGF showed 
only partial synergistic effects compared to control 
(Figure 2A). Additional MTS assays performed with 
SW480 (Figure 2B) and HCT116 (Figure 2C) colon 
cancer cells showed similar influences of PDGF (SW480: 
p<0.05 (48h); p<0.01(72h)), and VEGF (SW480: p<0.001 
(24h and 48h); p<0.01 (72h); HCT116: p<0.05 (24h and 
48h); p<0.01 (72h)) on tumor cell proliferation. After 72 
hours of stimulation with PDGF and/or VEGF, HT29 
cells showed a higher cell number in the cell count 
compared with unstimulated controls (Figure 2D). Gene 
expression of the proliferation marker KI67 was also 
increased in these cell lines (HT29: Figure 2I, HCT116: 
supplementary Figure S5A, and SW480: supplementary 
Figure S5B), which confirmed an accelerated cell cycle 
and an increased proliferative effect provoked by PDGF 
and VEGF, primarily after 24 hours.
To check the proliferative influence of PDGF on the 
PI3K/Akt/mTOR pathway, inhibition of the central Akt 
protein with InSolution™ Akt Inhibitor IV was conducted. 
Inhibition of Akt significantly reduced cell proliferation 
(Figure 2E), but 30 minutes after Akt inhibition, treatment 
with PDGF and VEGF attenuated the anti-proliferative 
effect caused by the Akt inhibitor. After 24 hours, neither 
PDGF nor VEGF suppressed the inhibitory effect on cell 
proliferation (Figure 2E). After 24 hours of incubation 
with the Akt inhibitor, the morphological appearance 
of HT29 cells was adversely affected compared with 
untreated control cells (Figure 2F).
Effects of PDGF and PI3K/Akt-pathway 
inhibition on apoptosis
Next to tumor cell proliferation, the influence of 
PDGF and/or PI3K/Akt-pathway inhibition on apoptosis 
in HT29 colorectal cancer cells was investigated. In 
the live/dead cell staining assay, PDGF (Figure 3C), 
VEGF (Figure 3B), and both PDGF and VEGF (Figure 
3D) slightly increased the amount of living cells (green 
staining) compared to untreated HT29 cells (Figure 3A). 
Furthermore, stimulation (Figure 3F-3H) decreased the 
amount of dead cells in presence of the Akt inhibitor 
compared to exclusive Akt inhibition (Figure 3E). The Akt 
inhibition showed an increased amount of dead cells (read 
staining) (Figure 3E) compared to control cells (Figure 
3A). During PI3K inhibition the proportion of dead cells 
remained unaltered (Figure 3I). Thus treatment of PDGF 
and VEGF (Figure 3J-3L) in presence of the PI3K inhibitor 
(Figure 3I) did not result in an increased survival of cells. 
The additionally performed ApopTag® Plus apoptosis assay 
showed comparable results (Supplementary Figure S1).
In flowcytometric AnnexinV apoptosis analysis, 
the overlay histograms of HT29 cells demonstrated 
a reduction of dead cells (right peak) in samples 
additionally supplemented with VEGF and/or PDGF 
60 to 240 minutes past treatment compared to exclusive 
treatment with the Akt inhibitor (Figure 4A). Additionally, 
PDGF exhibited a decreased proportion of dead cells 
compared to VEGF after 120 minutes (Figure 4A). 
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Figure 1: PDGF and VEGF expression in human colon cancer probes and in HT29 cell line. Significantly increased gene 
expression of PDGF A. and VEGF B. in human colon cancer probes in UICCI/II and III/IV. Normalization was performed with normal 
2-∆∆Cq. *p<0.05, **p<0.01, ***p<0.001. C. Immunofluorescence double staining of colon cancer tissue UICC III/IV exhibited a positive 
expression of PDGF (Cy3, red) and VEGF (Cy3, red) in epithelial (Cytokeratin, Alexa 488, green) cancer tissue but no or occasionally 
low expression in stromal regions (Vimentin, Alexa 488, green) with PDGF or VEGF. Magnification x20. D. Cytospin of HT29 cells with 
positive PDGF or VEGF staining. E. Immunofluorescence staining showed a positive expression of PDGF (Cy3, red) and VEGF (Cy3, red), 
nuclear counterstaining with DAPI blue.
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Figure 2: Influence of PDGF stimulation and Akt-pathway inhibition on proliferation in HT29, SW480, and HCT116 
J. PDGF and VEGF stimulation enhanced cell proliferation in the MTS assay in HT 29 A., SW480 B., and HCT116 cells C. D. Increased 
cell number after PDGF and VEGF stimulation (PDGF and VEGF stimulation 100 ng/ml, new stimulation every 24h). E. Akt inhibition 
(10 μM) induced a decreased proliferative effect in the MTS assay in HT29 cells. F. show the antiproliferative effect of the Akt inhibition 
compared with untreated control cells. G and H. Lower panels showed representative western blots and upper panels showed quantification 
of three independent western blot experiments of pRb (Ser 807/811) (G), and pRb (Ser 795) (H), normalized to β-Actin loading control. 
The tumor suppressor Rb was inactivated during PDGF stimulation and activated during Akt inhibition. I. The proliferation marker KI67 
was increased on gene level during PDGF and VEGF stimulation. *p<0.05, **p<0.01, ***p<0.001.
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The transition between the peak of the living cells (left 
peak) and the dead cells (right peak), which represents 
the proportion of apoptotic cells, showed that PDGF and 
VEGF increased the proportion of apoptotic cells and 
reduced the amount of dead cells.
Moreover, proportions of viable cells were found 
elevated in samples additionally incubated with VEGF 
and/or PDGF compared to sole Akt inhibition 60 to 
240 minutes past treatment. Correspondingly, reduced 
proportions of damaged cells (apoptotic and necrotic) 
Figure 3. Effect of PDGF stimulation and/or Akt- and PI3K inhibition on apoptosis - Live/Dead Cell staining assay. 
Single treatment with PDGF C. VEGF B. or PDGF + VEGF D. showed decreased amounts of dead cells (red) compared to Akt inhibitor 
treatment E. and control A. PDGF and VEGF stimulation F-H. decreased apoptosis (living cells, green). PI3K inhibition I. did not induce 
apoptosis, therefore PDGF and VEGF stimulation did not increase cell survival J-L. Magnification x10.
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Figure 4: Reduced cytotoxicity of Akt inhibition after additional treatment with PDGF and/or VEGF in AnnexinV 
apoptosis assay. A. Overlay histograms of AnnexinV fluorescence in cells treated with Akt inhibitor + VEGF, Akt inhibitor + PDGF, and 
Akt inhibitor + VEGF + PDGF compared to sole Akt inhibition demonstrated a reduction of dead cells (right peak) in samples supplemented 
with VEGF and/or PDGF 60 to 240 minutes past treatment. B. Proportions of viable cells were found elevated in samples additionally 
incubated with VEGF and/or PDGF compared to sole Akt inhibition 60 to 240 minutes past treatment. Correspondingly, reduced proportions 
of damaged cells (apoptotic, necrotic, and dead cells) were detected in samples additionally treated with VEGF and/or PDGF. VEGF + Akt 
inhibitor blue line, PDGF + Akt inhibitor green line, VEGF + PDGF + Akt inhibitor red line.
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were detected in samples additionally treated with VEGF 
and/or PDGF (Figure 4B).
Influence of PDGF and the Akt-pathway 
inhibition on tumor suppressor Rb
For a more detailed study of the influence of PDGF 
on cell cycle and proliferation, the effect of PDGF on the 
tumor suppressor Retinoblastoma (Rb) was investigated 
(Figure 2J). Rb controls transition of the G1-phase to 
the S-phase. It encloses the transcription factor E2F, but 
phosphorylation of Rb causes E2F release and leads to cell 
cycle progression [23, 24], because only free E2F is able 
to lead the cell cycle from the G1-phase into the S2-phase.
Stimulation with PDGF provoked increased 
phosphorylation and thus inactivation of Rb (p<0.01 
(60min) and p<0.001 (30 min and 24h) for pRb807/811, 
and p<0.05 (72h), and p<0.01 (30min) for pRb795). 
Inhibition of Akt showed a pronounced decline in the 
phosphorylation status of Rb (p<0.05 (60 min) and 
p<0.001 (24h) for pRb807/811 and p<0.001 (24h) for 
pRb795) and therefore more Rb activity, which resulted 
in more effective cell cycle control. PDGF decreased the 
effect of the Akt inhibitor (p<0.001 (30min) and p<0.01 
(60 min) for pRb807/811), and increased phosphorylation 
and hence inactivation of Rb (Figure 2G and 2H).
Effects of PDGF stimulation and Akt inhibition 
on the PI3K/Akt/mTOR pathway and MAPK 
pathway in colon cancer
To investigate PDGF induced influence on the 
PI3K/Akt/mTOR pathway, we first used a specific Akt 
inhibitor (InSolution™ Akt Inhibitor IV) (Figure 5H). 
Due to the inhibition of Akt, Akt protein expression was 
inactivated, but activated by PDGF (p<0.05) (Figure 5A). 
Synchronous inhibition and stimulation of HT29, HCT116 
(Supplementary Figure S2), and SW480 (Supplementary 
Figure S3) cells increased protein expression of Akt, 
compared to control and inhibitor, but decreased activity 
compared with exclusive stimulation with PDGF. 
Expression analysis of phosphorylated and thereby 
activated Akt (pAkt) showed the same results after a 
30-minute treatment. pAkt was deactivated during Akt 
inhibition, and upregulation was caused by stimulation 
with PDGF. However, after 60 minutes a reverse effect 
was observed. pAkt activity was significantly increased 
(p<0.001) (Figure 5B), and Akt was decreased by 
initiating Akt inhibition. The now-onset inhibition of 
Akt directly below pAkt in the downstream signaling 
cascade provoked reduced Akt protein and elevated pAkt 
protein expression (Figure 5A and 5B). Stimulation with 
PDGF resulted in a decreased pAkt and increased Akt 
(p<0.05) protein expression, by means of active PI3K/
Akt/mTOR signaling. PDGF mitigated the Akt inhibition 
and increased the PI3K/Akt/mTOR pathway activity 
(Figure 5B).
mTor (mammalian of rapamycin), S6 (S6 ribosomal 
protein), and 4E-BP1 (eukaryotic translation initiation 
factor 4E binding protein 1, p4E-BP1) are downstream 
targets of Akt. The translation repressor 4E-BP1 binds to 
eIF-4E (eukaryotic translation initiation factor 4E) and 
inhibits translation, protein synthesis, and proliferation. 
Phosphorylation, caused by mTOR, inactivated 4E-
BP1 [25–27]. mTOR and pS6 were inhibited by Akt 
inhibition (p<0.05), but activated after stimulation with 
PDGF (p<0.01 and p<0.001 respectively) (Figure 5C and 
5D). 4E-BP1 was dephosphorylated and thus translation 
was inactivated by Akt inhibition, but stimulation with 
PDGF increased the inactive, phosphorylated version 
of 4E-BP1 (p<0.05) (Figure 5E). Combined inhibition 
and activation showed a higher activity of pS6, p4E-
BP1, and pmTOR (p<0.01 after 24 hours) than sole Akt 
inhibition in the colon cancer cell lines HT29, HCT116 
and SW480 (exception: SW480 cells showed a reverse 
4E-BP1expression pattern, Supplementary Figure S3E)
pErk, downstream target of the MAPK pathway 
[28], was significantly inactivated by Akt inhibition after 
24 hours (p<0.001). However, stimulation with PDGF did 
not activate pErk (Figure 5F). Interestingly, pMEK1/2, 
also part of the MAPK signaling but upstream of Erk, 
was not influenced by both PDGF and the Akt inhibitor 
(Figure 5G).
Effects of PDGF stimulation and PI3K inhibition 
on the PI3K/Akt/mTOR and MAPK pathway in 
colon cancer
The second analyzed inhibition target of the 
PI3K/Akt/mTOR pathway was PI3K in HT29, HCT116 
(Supplementary Figure S4A-S4D), and SW480 
(Supplementary Figure S4E-S4H) colon cancer cells. 
Unlike the Akt inhibition, and as expected, pAkt was 
significantly (p<0.01) inhibited after 30 minutes and 
further on after 60 minutes (p<0.01) by the PI3K 
inhibitor (Figure 6A). pS6 and p4E-BP1 activity was 
likewise suppressed, particularly after 30 minutes and 60 
minutes respectively (Figure 6B and 6C). Both targets 
were activated by stimulation with PDGF; parallel 
inhibition and stimulation showed higher expression than 
treatment with the PI3K inhibitor alone. Interestingly, 
pErk was significantly activated (p<0.01 after 30minutes 
and p<0.001 after 60minutes) by the PI3K inhibition 
(Figure 6D). pMEK, again, remained unmodified by 
PDGF and PI3K inhibition (Figure 6E).
Influence of PDGF on metabolism/glycolysis in 
colon cancer tissues
In primary colon cancer, a constitutively increased 
mRNA expression of the glycolysis markers GLUT1, 
LDHA, and MCT4 (Figure 7I) was observed. GLUT1 
was significantly augmented in all tumor stages (p<0.001) 
(Figure 7A); LDH also showed a higher expression in all 
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stages (Figure 7B). MCT4 exhibited a significantly higher 
expression in particular at advanced stages (p<0.001) 
(UICC III/IV) compared to controls, and patients with 
colon adenomas (Figure 7C).
After 24 hours of initial stimulation with PDGF, 
GLUT1 showed a significantly increased expression 
(p<0.05) in HT29 cells (Figure 7D). Increased LDHA 
and MCT4 gene expression followed after 48 hours and 
72 hours upon stimulation with PDGF (Figure 7E and 
7F). Stimulation with VEGF provoked an attenuated 
expression of GLUT1, LDHA and MCT4, compared to 
controls, but only after 72 hours of stimulation. HCT116 
and SW480 cells exhibited the same expression patttern 
(Supplementary Figure S5C-S5H). GLUT1 and MCT4 
activity were reduced during Akt inhibition on protein 
level in HT29 cells (Figure 7G and 7H).
Figure 5: Western Blot analysis showed the effects of PDGF stimulation and/or Akt inhibition on the PI3K/Akt/mTOR 
and MAPK pathway in HT29 cells H. Lower panels show representative western blots and upper panels show quantification of three 
independent western blot experiments of Akt A., pAkt B., pmTOR C., pS6 D., p4E-BP1 E., and pErk F., normalized to Actin or Cofilin 
loading control. Cells were treated with Akt Inhibitor IV (10 μM) or PDGF (100 ng/ml), and with both Akt inhibitor and PDGF. Results are 
presented as ±SD. *p<0.05, **p<0.01, ***p<0.001. Representative western blots of pMEK 1/2 G. during Akt inhibition (loading control 
Cofilin).
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Figure 6: Western Blot analysis representing the effects of PDGF stimulation and/or PI3K inhibition on the PI3K/Akt/
mTOR and MAPK pathway in HT29 cells F. Lower panels show representative western blots and upper panels show quantification 
of three independent western blot experiments of pAkt A., pS6 B., p4E-BP1 C., and pErk D., normalized to Actin or Cofilin loading control. 
Cells were treated with PI3K Inhibitor (80 nM) or PDGF (100 ng/ml), and with both PI3K inhibitor and PDGF. Results are presented as 
±SD. *p<0.05, **p<0.01, ***p<0.001. E. Representative western blot of pMEK 1/2 during PI3K inhibition (loading control Cofilin).
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Figure 7: Influence of PDGF on glycolysis in human colon cancer probes and in HT29 cell line I. Gene expression of the 
glycolysis markers GLUT1 A., LDHA B., and MCT4 C. was activated on gene level at stage UICC III/IV in the human colon cancer probes. 
Results were presented as ±SD. *p<0.05, ***p<0.001. D-F. HT29 cells were treated with PDGF or VEGF or both PDGF and VEGF (100 
ng/ml respectively) for 24 hours, 48 hours, and 72 hours. The glycolysis markers GLUT1 (D), LDHA (E), and MCT4 (F) were activated on 
gene level mainly during PDGF stimulation but also during VEGF stimulation. Representative western blots of GLUT1 G., and MCT4 H. 
during Akt inhibition (loading control Cofilin), n=3.
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Influence of PDGF on oxygen consumption, 
glucose and lactate transport, and mitochondrial 
comlexes in HT29 colon cancer cells
The use of glucose transporter 1 (GLUT1) 
inhibitor IV, WZB117, caused a decreased glucose 
uptake into HT29 colon cancer cells, whereas a higher 
glucose influx was detected during stimulation with 
PDGF (Figure 8A). Interestingly, during PDGF influence 
the glucose uptake of colon cancer cells was increased, 
even in presence of the GLUT1 inhibitor. Release of 
lactate, as a product of glycolysis, was reduced during 
GLUT1 inhibiton, and enhanced during stimulation 
with PDGF (Figure 8B). Stimulation with PDGF caused 
higher glucose uptake into tumor cells and increased 
lactate release after 15 minutes of treatment (Figure 8A 
and 8B).
While PDGF stimulated glucose and lactate 
metabolism, oxygen consumption during stimulation with 
PDGF and VEGF remained unchanged (Figure 8C).
Measurement of the mitochondrial complexes I-V 
revealed a loss of activity during stimulation with PDGF 
and VEGF, compared to unstimulated tumor cells, at 
which PDGF showed a stronger inhibitory effect compared 
to VEGF (Figure 8D-8H). These data indicate a decreased 
mitochondrial activity and an increased glycolysis during 
PDGF stimulation.
Investigation of HIF1α and c-Myc in colon 
cancer
HIF1α and c-Myc take central positions in glycolysis 
regulation and thus in proliferation (Figure 9E). In primary 
colon tumors of patients, especially at advanced stages 
(UICC III/IV), a significantly higher gene expression of 
HIF1α (p<0.001) was observed (Figure 9A). Stimulation 
with PDGF also resulted in increased HIF1α expression in 
HT29 colon cancer cells, which was further intensified after 
stimulation with VEGF (p<0.05) after 48 hours (Figure 9B).
Activated c-Myc was significantly suppressed 
during Akt inhibition (p<0.001) in HT29 cancer cells 
(after 60 minutes and 24 hours of incubation), but PDGF 
significantly increased the c-Myc activity after 24 hours 
of stimulation (p<0.01) (Figure 9C). During PI3K 
inhibition, similar but attenuated effects were visible 
during stimulation with PDGF (after 60 minutes: p<0.05 
to control; p<0.01 to PI3K inhibition, and to PDGF+PI3K 
inhibition), and during Akt inhibition (Figure 9D).
DISCUSSION
PI3K/Akt/mTOR and MAPK pathway
Recent studies provide growing evidence of 
the important role of PDGF in colorectal cancer [29]. 
However, the influence of PDGF in colorectal cancer 
appears to be multifactorial and not completely understood 
in all aspects. We analyzed the PDGF expression in human 
colon cancer and dissected its role upon stimulation in 
colon cancer cells. We also compared the effects of PDGF 
with those from VEGF for most of the experiments.
In human colon cancer, PDGF and VEGF were 
highly expressed in all stages (UICC I-IV), which 
underlined an involvement of both PDGF and VEGF in 
tumor progression. HT29 cancer cells also secreted VEGF, 
and PDGF, which suggested an autocrine stimulation 
of the cancer cells (Figure 10). Based on this, we felt a 
precise investigation of the role of PDGF on colon cancer 
cells was appropriate.
Stimulation with both, PDGF and VEGF, showed 
an increased proliferative response in HT29 colon cancer 
cells, whereby VEGF exhibited a greater effect on 
proliferation. However, the combined stimulation with 
PDGF and VEGF showed no synergistic effects, which 
suggests a competitive mechanism in the cells [30].
Possible influences of PDGF on proliferation could 
be an activating effect of PDGF on the PI3K/Akt/mTOR 
pathway and a supplementary inhibition of the tumor 
suppressor Retinoblastoma (Rb), and thus activation of 
the cell cycle. Simultaneously, an activation of Rb was 
detectable during PI3K/Akt/mTOR pathway inhibition, 
reinforcing the antiproliferative effect of Rb [31]. 
Stimulation with PDGF induced an activation of the 
PI3K/Akt/mTOR pathway, while the MAPK pathway was 
unaffected by its stimulation, which confirms other results 
[32]. This showed that PDGF operates through the PI3K/
Akt/mTOR pathway and not through the MAPK pathway 
in CRC.
Interestingly, the two inhibiting substances, Akt 
inhibitor IV (Akt inhibitor) and PKI-179 (PI3K inhibitor), 
showed different effects on HT29, HCT116, and SW480 
cancer cell proliferation. While the Akt inhibitor 
demonstrated dramatic antiproliferative effects on these 
cells, the PI3K inhibitor revealed only marginal effects on 
cell proliferation.
It is well known that the PI3K/Akt/mTOR and 
the MAPK pathways are connected via crosstalk bonds 
[9, 10, 33]. Further investigation of the MAPK pathway 
demonstrated the specific inhibitory crosstalk [10] 
bond between PI3K/Akt/mTOR pathway, namely the 
Akt and MAPK pathway, primarily Erk. Our protein 
analysis after Akt inhibition showed an activation of 
pAkt and downregulation of pmTOR, pS6 and p4E-
BP1, downstream targets of Akt [34, 35]. This resulted 
in identification of the specific inhibition position found 
directly downstream after Akt phosphorylation. The Akt 
inhibitor caused an increased phosphorylation of Akt after 
60 minutes, but the signal was blocked downstream, and 
caused a visible downregulation of pS6, pmTOR, and p4E-
BP1 protein expression after 24 hours. pErk activity was 
also suppressed, because the inhibitory crosstalk was still 
active due to the boosted Akt phosphorylation. The three 
investigated cell lines showed consistency in the results, 
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Figure 8: Glucose and Lactate measurement, Oxygen consumption, and mitochondrial complexes activity in HT29 
cells. A and B. 1 × 106 cells were stimulated with PDGF (100 ng/ml) for 24 hours. Unstimulated cells and cells treated with PDGF were 
washed with glucose-free buffer (110mM NaCl, 5mM KCl, 1mM MgCl2, 4mM Na2PO4, 50mM Na-HEPES, pH 7.4), and treated with 
Glucose (20mM), GLUT1 inhibitor WZB117 (10 μM) or both. Glucose uptake (A), and lactate release (B) was measured with an abcam 
Glucose and Lactate Assay. HT29 cells were treated with PDGF or VEGF or both PDGF and VEGF (100 ng/ml) for 24 hours, n=3. Oxygen 
consumption C. showed no changes during PDGF and/or VEGF stimulation. For mitochondrial activity measurement D-H., cells were 
treated with PDGF, VEGF or both for 30 minutes, and measured with a MILLIPLEX® human oxidative phosphorylation (OXPHOS) 
magnetic bead panel, n=2. PDGF and VEGF decreased the activity of the mitochondrial complexes.
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only 4E-BP1 in the SW480 cells exhibited an opposite 
protein expression. The earlier Dukes’ stage of SW480 
(SW480: Dukes’ B, HT29: Dukes’ C, HCT116: Dukes’ 
D), and thus an altered pattern of mutations, and the 
different MSI instability [36] could be responsible for this 
deviation. Despite this high mutational heterogeneity the 
results did not appear to be cell-specific, but common in 
colon cancer. This specific Akt inhibitor allows inhibition 
of both PI3K/Akt/mTOR and MAPK pathway at once, 
and subsequently inhibition of cancer cell proliferation 
(Figure 5H).
PI3K inhibition showed an expected downregulation 
of pAkt and an increased activity of pErk because of the 
removal of the crosstalk inhibition of Akt. The MAPK 
pathway seemed to compensate the reduced proliferation 
of the PI3K/Akt/mTOR pathway during PI3K-inhibition 
(Figure 6F). Our data support the necessity to inhibit 
both, the PI3K/Akt/mTOR, and the MAPK pathway. But 
Figure 9: Investigation of HIF1α in human colon cancer probes (A), and in HT29 cells (B) and c-Myc (C and D) in 
HT29 cells (E). Gene expression of HIF1α was increased on gene level at stage UICC III/IV in the human colon cancer probes A. and 
during PDGF- and VEGF-stimulation (100 ng/ml) in HT29 cells B. C and D. Lower panels show representative western blots and upper 
panels show quantification of three independent western blot experiments of pc-Myc (S62), normalized to β-Actin loading control. Pc-Myc 
activity was increased by PDGF, and decreased by Akt inhibitor. Cells were treated with PDGF (100 ng/ml), Akt inhibitor IV (10 μM) (C) 
or PI3K Inhibitor (80 nM) (D). Results are presented as ±SD, *p<0.05, **p<0.01, ***p<0.001.
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single inhibition of the PI3K/Akt/mTOR pathway at the 
right location would be preferable to induce significant 
tumor cell damage, as inhibition of both pathways may 
otherwise cause additional clinical side effects. Therefore, 
future studies should focus on finding a PI3K/Akt/mTOR-
specific inhibitor that also inhibits compensatory crosstalk 
with the MAPK pathway.
Apoptosis and cell death
To closer investigate the morphological changes and 
dramatic antiproliferative effect of HT29 cells during Akt 
inhibition, cell death and apoptosis were examined. During 
Akt inhibition, HT29 cells exhibited not only cell death, 
indicating morphological changes. They also exhibited 
an increased proportion of dead cells, demonstrating the 
apoptotic influence of the Akt inhibitor. On the other hand, 
PDGF, VEGF, and both PDGF and VEGF, decreased the 
proportion of dead cells in presence of the Akt inhibitor 
compared to exclusive inhibition. These data indicate an 
apoptosis-preventing effect of PDGF; the PI3K inhibitor 
marginally increased the proportion of dead cells.
PDGF also appeared to have a cytoprotective effect 
on HT29 cells during Akt inhibition. In the AnnexinV 
analysis, stimulation with PDGF and VEGF increased the 
proportion of both living cells and apoptotic/necrotic cells. 
PDGF and VEGF, correspondingly, decreased the amount 
of dead cells despite Akt inhibition; particularly PDGF, 
but also VEGF delayed HT29 cell death. Combined 
stimulation with PDGF and VEGF exhibited a similar 
cytoprotective effect than sole PDGF stimulation, an 
indication that PDGF possessed a stronger anti-apoptotic 
effect. Percentage analyses of the living/dead cell ratio 
also clarified the anti-apoptotic potential of PDGF and 
VEGF: their cytoprotection increased the proportion of 
living cells and reduced the proportion of damaged cells 
(apoptotic, necrotic, and dead cells), in comparison to sole 
Akt inhibition.
Figure 10: Effects of PDGF on tumor cell signaling, and metabolism. PDGF decreases apoptosis, and increases glycolysis 
and proliferation in an Akt-dependent manner in CRC. It also activates HIF1α, and C-Myc, and suppresses Rb to accelerate metabolism 
and the proliferative potential of PDGF. This stimulating mechanisms highlight the importance and the potential of the PDGF-PI3K/Akt/
mTOR pathway-axis as a possible target in colorectal cancer. PDGF, platelet-derived growth factor; PI3K, phosphoinositide 3-kinase; 
mTOR, target of Rapamycin; HIF1α, hypoxia-inducible-factor 1α; Rb, Retinoblastoma; GLUT1, glucose transporter 1; LDHA, lactate 
dehydrogenase A; MCT4, monocarboxylate transporter 4.
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Glucose metabolism
Stimulation with PDGF can provoke changes in 
metabolism of colon cancer cells by activation of the PI3K/
Akt/mTOR pathway [16]. Therefore the consequences 
of PDGF on glycolysis were investigated. The glucose 
transporter 1 (GLUT1) regulates glucose uptake [16, 37, 
38], the lactate dehydrogenase A (LDHA) converts pyruvate 
to lactate [16, 38–40] and the monocarboxylate transporter 4 
(MCT4) controlls release of lactate [16, 38, 41] (Figure 10). 
In many tumor cells the glycolytic shift towards “oxidative 
glycolysis” was strongly activated, instead of metabolizing 
glucose by oxidative phosphorylation (Warburg effect) [38, 
42, 43] to produce important biosynthetic intermediates for 
cell proliferation and hence tumor growth [16]. In HT29 
colon cancer cells, all three targets (GLUT1, LDHA and 
MCT4) were activated, and increased glucose uptake and 
lactate release by stimulation with PDGF was detectable. 
The data indicated a higher glycolytic rate in presence of 
oxygen, while oxygen consumption remained constant. The 
colon cancer cells regulate their energy metabolism more 
flexibly in the presence of PDGF. Unlike proliferation, 
where VEGF took the dominant role, PDGF instead seems 
to play the greater role in the conversion to malignant 
metabolism. These data suggest the posibility that PDGF 
and VEGF can act in a synergistic manner for accelerated 
cancer progression.
Primary human colon cancers demonstrated a 
significant activation of GLUT1, LDHA, and MCT4 gene 
expression, which supports the importance of glycolysis 
in colon cancer, particularly at late stages. Interfering with 
the PDGF-induced acceleration of glycolysis represents 
a potential target in tumor metabolism in all progression 
stages (Figure 10).
HIF and c-Myc
HIF1α, an important transcription factor, upregulates 
glycolytic enzymes like GLUT1 [16], LDHA [44, 45], 
and MCT4 [46]. Importantly, HIF1α expression can be 
activated by the PI3K/Akt/mTOR pathway [16, 38]. It is 
stabilized under hypoxia and supports the Warburg effect 
[16, 47]. In tumor cells it can be activated also under 
normoxic conditions (“pseudohypoxia”) [14, 48, 49].
The transcription factor and potential oncogene 
c-Myc influences proliferation, cell cycle, and cellular 
metabolism. c-Myc is overexpressed by the majority of 
colon cancers [50–52], and the human HT29 cancer cell 
line is known as c-Myc-positive. It is also known that 
c-Myc and HIF1α are able to collaborate with each other 
with great influence on aerobic glycolysis [45, 51, 53].
Investigation of HIF1α in human colorectal cancers 
of the patient cohort showed an increased expression 
in all tumor stages (UICC I-IV). In HT29 cancer cells, 
stimulation with PDGF and VEGF activated HIF1α; 
c-Myc was more activated during stimulation with PDGF 
and the inhibition of Akt showed a decrease in c-Myc 
activity. Obviously, PDGF increased activity of the 
HIF1α-c-Myc axis.
Akt inhibition reduced c-Myc activity, because both 
PI3K/Akt/mTOR and MAPK pathways were inhibited. 
The PI3K inhibitor, however, showed only moderate 
inhibitory effects on c-myc; in this case the MAPK 
pathway was activated due to the reverse inhibitory 
crosstalk between PI3K/Akt/mTOR and MAPK pathway.
The oncogenic potential of the transcription factors 
c-Myc and HIF1α has great influence on tumor energy 
metabolism and triggers tumor progression [54]. In this 
study, both HIF1α and c-Myc seemed to be related to 
PDGF and the PI3K/Akt/mTOR pathway (Figure 8). 
Inactivation of PI3K/Akt/mTOR led to reduced c-Myc, 
GLUT1, and MCT4 activity. PDGF mediated activation 
of PI3K/Akt/mTOR, and subsequent activation of HIF1α 
and c-Myc, resulting in activation of GLUT1, LDHA, and 
MCT4. This contributes to increased aerobic glycolysis/
Warburg effect [14, 15, 17, 50, 53, 55] and proliferation 
in CRC.
In conclusion, PDGF activates the PI3K/Akt/mTOR 
pathway, and suppresses apoptosis, even in presence of 
the Akt inhibitor. PDGF also activates HIF1α, and c-Myc, 
increases glycolysis and suppresses the tumor suppressor 
Rb, resulting in modified tumor metabolism and increased 
proliferation. The anti-apoptotic, pro-metabolic, and pro-
proliferating effect of PDGF catalyzes colorectal cancer 
progression (Figure 10).
More in-depth investigations of specific crosstalk 
connections between signaling pathways need to be 
performed. The use of targeted therapy in CRC needs to 
be highly selective to block possible escape mechanisms 
amongst the intracellular signal pathways efficiently. A 
better understanding of pathway crosstalks should be the 
aim of future studies to negate possible effects of “over 
inhibition” of pathways, resulting in clinical side effects in 
patients. Our data highlight the importance of the PDGF-
PI3K/Akt/mTOR pathway-axis and its potential as a 
possible weak point in colorectal cancer.
MATERIALS AND METHODS
Tissue samples
Colon cancer tissue samples, and corresponding 
normal mucosa samples were obtained from 46 patients 
(5 adenoma, 19 patients UICC I/II, 22 patients UICCIII/
IV), undergoing curative surgical resection in our surgical 
department between 09/2009 and 05/2013. From all 
patients an informed consent was obtained before tissues 
were collected. Ethical approval was obtained from the 
Human Research Ethics Committee of the University of 
Wuerzburg. All patients providing colon cancer samples 
signed a consent form to allow for this research. The 
stage classification of the tumor tissue was determined 
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according to the Union Internationale Contre le Cancer 
(UICC) system.
Materials
PDGF-BB was purchased from Miltenyi Biotech 
(Bergisch Gladbach, Germany), VEGF-165 from R&D 
Systems (Minneapolis, MN, USA). InSolution™ Akt 
inhibitor IV, and PI3K inhibitor PKI-179 were obtained 
from Calbiochem, (San Diego, CA, USA). The Glucose 
Transporter Inhibitor IV, WZB117, was purchased from 
Merck Millipore (Darmstadt, Germany).
Cancer cell lines and culture
The human colon cancer cell lines HT29, SW480, 
and HCT116 and the appropriate medium were obtained 
from ATCC (Manassas, VA, USA) and cells were cultured 
at 37°C in 5% CO2. HT29, and HCT116 cells were 
cultured in McCoy’s 5A Medium, SW480 cells were 
cultured in RPMI medium, medium was supplemented 
with 10% (v/v) fetal bovine serum, and 1% (v/v) 
penicillin/streptomycin (both Life Technologies Carlsbad, 
CA, USA). We exemplarily used the HT29 colorectal 
cell line for most of the experiments. For representative 
substantiation, additionally, the SW480 and HCT116 cell 
line were used.
Antibodies
For Western Blot immunostaining procedure, 
the membranes were incubated with Akt, phospho-Akt 
(Ser473) (D9E), phospho-S6 (Ser235/236) (D57.2.E), 
phospho-4E-BP1 (Thr37/46) (236B4), phospho-mTOR 
(Ser248) (D9C2), β-Actin (13E5), Cofilin (D3F9) 
(HRP conjugate), GAPDH (D16H11) (HRP conjugate), 
α-Tubulin (11H10) (HRP conjugate), phospho-Rb 
(Ser807/811), phospho-Rb (Ser795), phospho-p44/42 
MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E), phospho-
MEK1/2 (Ser217/221) (all purchased from Cell Signaling, 
Beverly, MA, USA), anti-c-Myc (phospho S62), anti–
Glucose Transporter GLUT1, and anti-MCT4 (both from 
abcam, Cambridge, UK). The blots were incubated with 
the HRP-conjugated secondary antibodies goat anti-
rabbit IgG or goat anti-mouse IgG (both from Santa Cruz 
Biotechnology, Dallas, TX, USA).
Methods
Quantitative real time polymerase chain reaction 
(real time PCR)
Gene expression of PDGF, VEGF, HIF1α, GLUT1, 
MCT4, LDHA, and KI67 was analyzed in colon cancer 
specimens by real time PCR. VEGF served as a control for 
the PDGF gene profiling. Complementary DNA (cDNA) 
was performed using the ImProm-II reverse transcriptase 
system (Promega, WI, USA) and an Eppendorf 
Mastercycler (Eppendorf, Hamburg, Germany). The 
TaqMan gene expression assays were purchased from Life 
Technologies. All samples were assayed in duplicate and 
normalized during data analysis. The housekeeping genes 
β-Actin, 18S rRNA, and RPLP0 (ribosomal protein lateral 
stalk subunit P0) were used for relative quantification, the 
relative quantification value is expressed as 2-∆∆Cq. Results 
were normalized to colon normal tissue purchased from 
Biochain (Hayward, CA, USA). PCR reactions were 
conducted with a BioRad CFX96 Touch real-time PCR 
detection system.
Protein extraction and western blot analysis
Total protein extracts were assembled using 
RIPA lysis buffer Equal protein amounts (30-50 μg) 
were electrophoresed using NuPage Novex precast gels 
(Invitrogen/Life Technologies) and transferred with the 
iBlot dry blotting system (Invitrogen/Life Technologies). 
Bands were detected by ECL solution (Thermo Scientific, 
Waltham, MA, USA).
MTS proliferation assay
The proliferation rate of cells was checked with the 
colorimetric CellTiter 96 Aqueous One Solution assay 
(Promega, WI, USA). 2500 cells/96well were seeded in 
each well. Cells were stimulated with VEGF, PDGF or 
VEGF and PDGF (100 ng/ml respectively) for 24 hours, 
48 hours, and 72 hours under starving conditions.
For investigation of effect of the Akt inhibitor, cells 
were treated with VEGF, PDGF, or VEGF and PDGF 
and/or Akt inhibition (10 μM) for 30 minutes, 60 minutes 
and 24 hours. CellTiter 96® AQueous One Solution Cell 
Proliferation Assay was added to each well and measured 
according to the manufacturer’s instructions.
Live/dead cell staining assay
The proportions of live and dead cells after 
treatment with PDGF (100 ng/ml), VEGF (100 ng/ml) 
or VEGF + PDGF and simultaneous incubation of Akt 
inhibitor (10 μM) or PI3K inhibitor (80 nM) for 2 hours 
were investigated with a PromoKine live/dead cell staining 
kit II (PromoCell, Heidelberg, Germany). The assay was 
performed according to the manufacturer’s instructions, 
immunofluorescence was detected with an Olympus BX51 
microscope and the CellSens Dimension software.
ApopTag® Plus apoptosis assay
For apoptosis investigation, an ApopTag® Plus 
Peroxidase In Situ Apoptosis detection assay (Merck 
Millipore) was performed. After incubation of HT29 
cells with PDGF (100 ng/ml), VEGF (100 ng/ml) or 
VEGF + PDGF and simultaneous incubation of Akt 
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inhibitor (10 μM) or PI3K inhibitor (80 nM) for 2 hours, 
cells were fixed with formaldehyde overnight. Staining 
procedure was performed according to the manufacturer’s 
instructions. For immunofluorescence staining, a 
DyLight®594 Anti-Digoxigenin/Digoxin antibody 
(Vector, Burlingame, Ca, USA) and DAPI Fluoromount 
G mounting medium (Southern Biotech, Birmingham, Al, 
USA) was used. An Olympus BX51 microscope and the 
CellSens Dimension software was used for visualization, 
magnification x10.
AnnexinV apoptosis assay
Cells treated with Akt inhibitor (10 μM) were 
incubated simultaneously with PDGF (100 ng/ml), VEGF 
(100 ng/ml) or PDGF + VEGF and detached with accutase 
solution (Sigma-Aldrich) 30 minutes, 60 minutes, 120 
minutes, and 240 minutes after treatment. Cells were 
treated with AnnexinV-FITC Apoptosis Detection Kit 
(abcam) according to the manufacturer’s instructions and 
analyzed on a flow cytometer (Beckman Coulter, Krefeld, 
Germany) with a software package (Coulter, Epics XL-
MCL, System II).
MILLIPLEX assay for human oxidative 
phosphorylation
Tumor protein extraction and procedure was 
performed according to the manufacturer’s instructions 
(MILLIPLEX® human oxidative phosphorylation 
(OXPHOS) magnetic bead panel; purchased from Merck 
Millipore). The protein concentration was 10 μg, sample 
preparations and data collection were performed according 
to the manufacturer’s instructions. Values were given as 
median fluorescence intensity (MFI); n=2.
DAB- and immunofluorescence staining
For DAB- and immunofluorescence staining, HT29 
colon cancer cells were seeded on cover slips, fixed in 
formalin, and treated with the Dako EnVision™+ Dual 
Link System-HRP (DAB+) (Dako, Glostrup, Denmark) 
according to the manufacturer’s instructions. For DAB and 
immunofluorescence staining PDGF monoclonal antibody 
was purchased from Santa Cruz Biotechnology, and 
VEGF monoclonal antibody was purchased from abcam. 
Secondary antibody was incubated for 60 minutes (DAB 
staining: rabbit/mouse polymer, part of Dako EnVision™+ 
Dual Link System-HRP (DAB+); immunofluorescence 
staining: goat anti mouse IgH H&L, Cy3, abcam; DAPI 
Fluoromount G mounting medium). An Olympus BX51 
microscope and the CellSens Dimension software were 
used for visualization.
For immunofluorescence double staining, the 
colon cancer tissue slides were fixed in acetone and 
the antibodies bound during the first staining step were 
covered and fixed with Dako Doublestaining system, 
K1395 (Dako, Glostrup, Denmark), according to the 
manufacturer’s instructions. The immunofluorescence 
double staining (coexpression) was detected with VEGF 
and PDGF, panCytokeratin monoclonal antibodies (both 
from Santa Cruz), and Vimentin (from abcam). Rabbit 
anti-mouse Cy3, and goat anti-rabbit Alexa488 secondary 
antibodies were purchased from dianova, Hamburg, 
Germany. An Olympus BX51 microscope and the 
CellSens Dimension software was used for visualization.
Glucose transporter 1 inhibition
Cells were incubated for 24 hours with PDGF (100 
ng/ml) and washed with PBS twice. After detaching the 
cells 1 × 106 cells were treated with glucose and WZB117 
and/or PDGF for 15 minutes. Glucose and Lactate Assay 
(both from abcam) were performed according to the 
manufacturer’s instructions.
Oxygen measurement
Oxygen consumption of HT29 cancer cells 
was measured with the Oxytherm system (Hansatech 
Instruments). The Oxytherm system was used in 
accordance with the manufacturer’s instructions. After 
the calibration was conducted, 1 × 106 treated or untreated 
cells in 1 ml media in each probe were measured with the 
Oxytherm device. Results after 0.5 minutes were evaluated 
with the Oxygraph plus software.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 5.0 (Graph Pad Software Inc., San Diego CA, 
USA). A Two-way ANOVA with Bonferroni post hoc 
test or a One-way ANOVA with post hoc tests according 
to sample distribution was used. Data were presented as 
mean ± standard deviation. p< 0.05 was considered to be 
statistically significant.
Quantification of Western Blot bands were analysed 
with Image Studio Lite. The relative densities of the bands 
were expressed as the percentage of the control.
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